|
Market Closed -
Swiss Exchange
11:31:13 2026-10-19 EDT
|
5-day change | 1st Jan Change | ||
| 124.20 CHF | -0.40% |
|
+3.53% | +13.32% |
| 10-19 | Novartis Halts Phase 2 Study of Iptacopan in Lupus Nephritis | MT |
| 10-19 | Switzerland's Blue-chip Index Kicks Off Week Downbeat; Novartis Shares Decline | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 288B | |||||
| 1,120B | |||||
| 616B | |||||
| 504B | |||||
| 367B | |||||
| 360B |
- Stock Market
- Stocks
- NOVN Stock
- Charts Novartis AG
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
